insurance changes to glp 1 drugs CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Why payers are hesitant to
Description
Now, the FDA has announced a timeline for when most compounded versions may no longer be made
Docwire News
Although this has been found to be the case, it was also found that other preprocedural GI effects were observed with a higher incidence in GLP-1 RA users such as reduced gastric acidity, nausea, vomiting, dyspepsia, and abdominal distension (OR 15.1
Individuals with one copy of the variant lost an average of 0.76 kg more than those without it, and those with two copies lost 1.52 kg more
These changes present both challenges and opportunities for stakeholders throughout the food value chain
